These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32050809)

  • 1. Use of oral antidiabetic drugs in Japanese working-age patients with type 2 diabetes mellitus: dosing pattern for metformin initiators.
    Kameda T; Kumamaru H; Nishimura S; Kohsaka S; Miyata H
    Curr Med Res Opin; 2020 May; 36(5):749-756. PubMed ID: 32050809
    [No Abstract]   [Full Text] [Related]  

  • 2. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017.
    Wilkinson S; Douglas I; Stirnadel-Farrant H; Fogarty D; Pokrajac A; Smeeth L; Tomlinson L
    BMJ Open; 2018 Jul; 8(7):e022768. PubMed ID: 30056393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of oral antidiabetic drug prescribing patterns based on the body mass index for Japanese type 2 diabetes mellitus patients and yearly changes in diabetologists' prescribing patterns from 2002 to 2019 (JDDM61).
    Yagi N; Komiya I; Arai K; Oishi M; Fukumoto Y; Shirabe S; Yokoyama H; Yamazaki K; Sugimoto H; Maegawa H;
    J Diabetes Investig; 2022 Jan; 13(1):65-73. PubMed ID: 34191401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of effectiveness and drug cost between dipeptidyl peptidase-4 inhibitor and biguanide as the first-line anti-hyperglycaemic medication among Japanese working generation with type 2 diabetes.
    Ihana-Sugiyama N; Sugiyama T; Tanaka H; Ueki K; Kobayashi Y; Ohsugi M
    J Eval Clin Pract; 2020 Feb; 26(1):299-307. PubMed ID: 31161662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to modification of antidiabetic therapy in patients over the age of 65 years with newly diagnosed diabetes mellitus.
    Machado-Alba JE; Machado-Duque ME; Gaviria-Mendoza A
    Diabetes Res Clin Pract; 2020 Apr; 162():108090. PubMed ID: 32088311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
    Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
    JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country.
    Zaghloul N; Awaisu A; Mahfouz A; Alyafei S; Elewa H
    Int J Clin Pharm; 2022 Dec; 44(6):1342-1350. PubMed ID: 36169802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes.
    Ou HT; Chang KC; Li CY; Wu JS
    Br J Clin Pharmacol; 2017 Jul; 83(7):1556-1570. PubMed ID: 28109184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in prescription patterns and doses of oral antidiabetic drugs in Japanese patients with type 2 diabetes (JDDM70).
    Shirabe S; Yamazaki K; Oishi M; Arai K; Yagi N; Sato M; Takeuchi M; Kai T; Maegawa H
    J Diabetes Investig; 2023 Jan; 14(1):75-80. PubMed ID: 36268571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes.
    Zhou Y; Geng Z; Wang X; Huang Y; Shen L; Wang Y
    Diabetes Metab Res Rev; 2020 Feb; 36(2):e3223. PubMed ID: 31642583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan.
    Bouchi R; Sugiyama T; Goto A; Imai K; Ihana-Sugiyama N; Ohsugi M; Yamauchi T; Kadowaki T; Ueki K
    J Diabetes Investig; 2022 Feb; 13(2):280-291. PubMed ID: 34309213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y; Hong T
    Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
    Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
    BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Kawalec P; Mikrut A; Łopuch S
    Diabetes Metab Res Rev; 2014 May; 30(4):269-83. PubMed ID: 24829965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus.
    Kim J; Park S; Kim H; Je NK
    Eur J Clin Pharmacol; 2019 Dec; 75(12):1723-1730. PubMed ID: 31475315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.